The Ross operation as a combined procedure and in complicated cases--is there an increased risk?

The Thoracic and Cardiovascular Surgeon
Jürgen O BöhmJoachim-Gerd Rein

Abstract

In this report we address the question whether the Ross operation can be recommended in combined and complicated cardiac procedures. From February 1995 to July 2000, we performed 203 Ross operations, 129 with ideal clinical presentation (group 1: mean age 41 +/- 13 years, male 105). In 74 patients, the clinical presentation was complex (group 2: mean age 35 +/- 17 years, male 57), defined as previous aortic or cardiac operations in 32, active endocarditis in 8 or combined procedures in 40 patients. Follow-up is 95 % complete. Neither early mortality nor thromboembolic events were observed. Complications in group 1 vs. group 2 were prolonged ventilation in 1 vs. 1, pacemaker insertion in 1 vs. 2, minor myocardial infarction in none vs. 2 and postoperative bleeds in 2 vs. 3 patients. In group 1, one patient died of hemoptysis at 25 months, and in group 2 one sudden death occurred at 5 months. In the long term, two patients required reoperation for autograft failure in group 1, and one on group 2. Pulmonary stenosis required surgical treatment in one patient of group 2. Echocardiography revealed physiological gradients across the autograft with no significant regurgitation in either group. The Ross operation has excellent mid-term...Continue Reading

Citations

Jun 30, 2004·The Annals of Thoracic Surgery·Cornelius A BothaWolfgang Hemmer
Sep 28, 2013·The Annals of Thoracic Surgery·T Brett ReeceJames S Gammie
Jan 24, 2009·The Annals of Thoracic Surgery·Jürgen O BöhmCornelius A Botha
Jul 28, 2004·The Annals of Thoracic Surgery·Jean-Michel GrindaAlain Deloche
Mar 21, 2003·The Annals of Thoracic Surgery·Jürgen O BöhmJoachim-Gerd Rein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.